Status:
ACTIVE_NOT_RECRUITING
Immune Resolution After Staphylococcus Aureus Bacteremia
Lead Sponsor:
University of Chicago
Conditions:
Immune Response To Sepsis
Staphylococcus Aureus Infection
Eligibility:
All Genders
18+ years
Brief Summary
The purpose of this study is to determine how monocyte HLA-DR and other markers of immune function change with time in patients with and without prior immune dysfunction who survive sepsis from Staphy...
Eligibility Criteria
Inclusion
- At least one blood culture positive for S. aureus
- Patients aged ≥18 years
- At least two of four systemic inflammatory response syndrome (SIRS) criteria on the day of positive blood cultures. SIRS criteria are:
- Body temperature less than 36°C(96.8°F) or greater than 38°C(100.4°F)
- Heart rate greater than 90 beats per minute
- Tachypnea (high respiratory rate), with greater than 20 breaths per minute; or, an arterial partial pressure of carbon dioxide less than 32 mmHg
- WBC less than 4000 cells/mm³ (4 x 109 cells/L) or greater than 12,000 cells/mm³ (12 x 109 cells/L); or the presence of greater than 10% immature neutrophils (band forms)
Exclusion
- Sequential Organ Failure Assessment (SOFA) score \> 12 on day of positive blood cultures
- Survival expected to be \< 7 days from positive blood cultures
Key Trial Info
Start Date :
June 1 2013
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
June 1 2026
Estimated Enrollment :
102 Patients enrolled
Trial Details
Trial ID
NCT01879761
Start Date
June 1 2013
End Date
June 1 2026
Last Update
August 14 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Chicago Hospital
Chicago, Illinois, United States, 60637